Press

About Re:Cognition Health

Re:Cognition Health is a leading brain and mind health specialist, providing advanced diagnostics, treatment, and support for conditions such as Alzheimer’s, dementia, concussion, and cognitive disorders. Its expert clinicians use cutting-edge technology, clinical trials, and personalized care plans to deliver early, accurate diagnoses and effective interventions. With a focus on improving quality of life, Re:Cognition Health offers multidisciplinary support for patients and families, helping people understand symptoms, access the latest treatments, and manage long-term brain health with confidence.

A global leader in Alzheimer’s Disease research and treatment, Re:Cognition Health has been at the forefront of advancing treatments to slow the progression of the disease, from the early stages of clinical trials through FDA approvals and now treatment administration. It holds the distinction of being the first center in Europe to deliver amyloid-targeting therapies (ATT) to patients in a clinical setting; its clinical team is extremely experienced in these treatments, having administered more than 11,500 doses of ATT in the United States and the United Kingdom.

Re:Cognition Health By the Numbers

• Founded in the UK in 2011, expanded to the US in 2018
• 4 centers in the US
• 200+ employees
• 10,600+ patients treated

Meet the Experts

Dr. Emer MacSweeney BSc (Hons), MBBS, MRCP, FRCR 
Co-Founder & CEO of Re:Cognition Health’s Brain and Mind Clinics, UK & USA

Dr. Emer MacSweeney is a world-renowned expert in brain and mind health, including the diagnosis and available treatments for Alzheimer’s disease, as well as CTE.

She is the co-founder, CEO, and medical director of Re:Cognition Health, which provides a specialist service for the accurate diagnosis and treatment of progressive neurodegenerative and neurodevelopmental conditions, as well as traumatic brain injury. The company has 10 centers across the US and the UK where patients can receive a diagnosis, participate in global clinical trials for new diagnostic biomarkers and emerging medications, and access available treatment options for symptoms of Alzheimer’s disease.

Dr. MacSweeney has been involved from the early days of clinical trials for the treatment of Alzheimer’s disease symptoms and was the first clinician in Europe to administer Amyloid Targeting Therapy (ATT) drug Kinsula to patients outside of a clinical trial. The Re:Cognition Health team has administered more than 12,500 doses of ATT medications and is one of, if not the, largest providers of these therapies in Europe.

In addition to her clinical and research leadership, Dr. MacSweeney is a sought-after speaker at global conferences, is frequently quoted in international media, and has two TEDx Talks focused on Alzheimer’s disease and CTE which have garnered millions of views on YouTube.

Previously, she served as Director of Neuroradiology at Atkinson Morley’s Hospital, St George’s Healthcare Trust, and Managing Director at MedTel UK. Dr. MacSweeney has a special interest in the neuroradiology of cognitive impairment disorders with considerable experience in imaging of neurovascular diseases and traumatic brain injury.

She trained in neuroradiology at The Hospital of Neurology and Neurosurgery, Queen’s Square, specializing in interventional vascular neuroradiology, and spent time on a scholarship at Harvard University.

Dr. MacSweeney and Re:Cognition Health’s expertise has been recognized with more than 40 prestigious and international accolades, including Inc. Female Founders 500 (2026), HealthInvestor’s Diagnostics Provider of the Year (2025), LaingBuisson Winner – Best in Healthcare Outcomes (2025), Leaders in Law Cognitive Health Expert of the Year (2024/2025), Global 100 Best Health Research Company of the Year UK (2023), EY Entrepreneur of the Year – Societal Impact (London and South England – 2019), and KPMG Entrepreneur of the Year (2016).

Dr. MacSweeney in the News

TEDx Talk: Our Brains are Dying Before Our Bodies

TEDx Talk: CTE: The Silent Killer in Contact Sports

Thrive Global: Maybe It’s Not Just Forgetfulness: Early Alzheimer’s Symptoms

BBC: Alzheimer’s Finger-Prick Test Could Help Diagnosis

Inc. Female Founders 500 2026

Tom S. Dent
Executive Chairman

Tom is a vision and values-based leader having built credibility across multiple stakeholders in the US and UK. Dent is also the Chairman/CEO of urgent care company, Urgent Team, and the Lead Director for HealthStream (NASDQ), a leading provider of workforce, patient experience, and provider solutions. Dent co-founded PhyCor (NASDQ), the pioneer of the Physician Practice/IPA Management industry. His previous leadership roles include international diagnostic imaging, managed care operations, hospital management and healthcare M&A. Dent was a founding Director of Healthcare Realty Trust (NYSE-HR) and earned a B.S. Degree from Mississippi State University and a Master’s Degree from George Washington University.

As Seen in

Emer MacSweeney TEDTalk: CTE – The Silent Killer in Contact Sports

The Brain and Mind Experts Podcast

Blog & Resources and Press Releases